Literature DB >> 16027153

Tyrosine phosphorylation of VE-cadherin prevents binding of p120- and beta-catenin and maintains the cellular mesenchymal state.

Matthew D Potter1, Simone Barbero, David A Cheresh.   

Abstract

In several pathological conditions, epithelial cells demonstrate a breakdown of barrier function and acquire an invasive phenotype. Endothelial cells in particular are maintained in a mesenchymal state during the cell invasion phase of angiogenesis. We show here that tyrosine phosphorylation of the adherens junction protein VE-cadherin at two critical tyrosines, Tyr-658 and Tyr-731, via tyrosine kinase activation or phosphatase inactivation was sufficient to prevent the binding of p120- and beta-catenin, respectively, to the cytoplasmic tail of VE-cadherin. In fact, phosphorylation at either site led to the inhibition of cell barrier function. Cells expressing wild-type VE-cadherin showed decreased cell migration compared with cells lacking VE-cadherin, whereas expression of VE-cadherin with a simple phosphomimetic tyrosine-to-glutamic acid mutation of Y658E or Y731E was sufficient to restore the migratory response. These findings demonstrate that a single phosphorylation event within the VE-cadherin cytoplasmic tail is sufficient to maintain cells in a mesenchymal state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027153     DOI: 10.1074/jbc.M505568200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  155 in total

1.  p120-Catenin prevents neutrophil transmigration independently of RhoA inhibition by impairing Src dependent VE-cadherin phosphorylation.

Authors:  Pilar Alcaide; Roberta Martinelli; Gail Newton; Marcie R Williams; Alejandro Adam; Peter A Vincent; Francis W Luscinskas
Journal:  Am J Physiol Cell Physiol       Date:  2012-05-30       Impact factor: 4.249

Review 2.  Recent insights into endothelial control of leukocyte extravasation.

Authors:  Peter L Hordijk
Journal:  Cell Mol Life Sci       Date:  2016-01-21       Impact factor: 9.261

3.  VE-cadherin phosphorylation decides: vascular permeability or diapedesis.

Authors:  Adama Sidibé; Beat A Imhof
Journal:  Nat Immunol       Date:  2014-03       Impact factor: 25.606

4.  Time-Variant SRC Kinase Activation Determines Endothelial Permeability Response.

Authors:  Jennifer E Klomp; Mark Shaaya; Jacob Matsche; Rima Rebiai; Jesse S Aaron; Kerrie B Collins; Vincent Huyot; Annette M Gonzalez; William A Muller; Teng-Leong Chew; Asrar B Malik; Andrei V Karginov
Journal:  Cell Chem Biol       Date:  2019-05-23       Impact factor: 8.116

5.  Metabotropic glutamate receptor 5 mediates phosphorylation of vascular endothelial cadherin and nuclear localization of β-catenin in response to homocysteine.

Authors:  Richard S Beard; Jason J Reynolds; Shawn E Bearden
Journal:  Vascul Pharmacol       Date:  2012-01-21       Impact factor: 5.773

6.  Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation.

Authors:  Kunihiko Hatanaka; Michael Simons; Masahiro Murakami
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-29       Impact factor: 4.733

Review 7.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596

Review 8.  Cellular and molecular regulation of vascular permeability.

Authors:  Lauren M Goddard; M Luisa Iruela-Arispe
Journal:  Thromb Haemost       Date:  2013-02-07       Impact factor: 5.249

9.  Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling.

Authors:  Angela J Glading; Mark H Ginsberg
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

10.  Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin.

Authors:  Li-Wu Qian; Whitney Greene; Fengchun Ye; Shou-Jiang Gao
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.